Temozolomide (CAS 85622-93-1) – Anticancer API

Temozolomide (CAS 85622-93-1) is a high-potency oral alkylating anticancer API, featuring a unique mechanism that crosses the blood-brain barrier to exert targeted cytotoxic effects on malignant cells. Its molecular structure undergoes spontaneous hydrolysis at physiological pH to release an active metabolite, which alkylates DNA and induces tumor cell apoptosis. Produced under strict GMP-certified processes, it ensures ultra-high purity, consistent bioactivity, and compliance with global oncology drug quality standards.

This premium API is a core raw material for pharmaceutical manufacturers developing treatments for central nervous system malignancies. It is widely applied in formulating oral medications for glioblastoma multiforme and anaplastic astrocytoma, often used as a first-line or adjuvant therapy combined with radiotherapy. With proven clinical efficacy in extending patient survival and improving quality of life, it addresses the critical demand for brain tumor-specific anticancer therapies. For R&D teams and production enterprises, it provides a trusted solution to advance precision oncology care for neuro-oncological disorders.